Peanut intake and liver health in adults with MASLD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional study assigns adults with MASLD to either an intervention of daily peanut consumption for 12 weeks or to continue their regular diet. Researchers will compare changes in liver tests, metabolic profiles, and gut microbes between groups, using blood samples, stool samples, and liver fat measurements when available. Participants will keep a daily peanut intake log and complete dietary recalls at baseline, Week 6, and Week 12 to track adherence. Post-intervention assessment may include FibroScan liver fat assessment if baseline data exist. The study aims to understand whether peanuts can positively influence liver health and metabolic outcomes in MASLD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 30-70 years
* do not consume peanut/peanut butter/treenut/seeds \> /week
* at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
* Able to understand, speak, and read English
* Mentally competent to consent

Exclusion Criteria:

* Food allergy to peanuts or peanut-containing products
* With alcohol use disorder (AUDIT screening)
* Leukemia
* Lymphoma
* Other types of cancer
* Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
* Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)

Where it's running

• Henry Ford Health System
  Detroit, Michigan, United States Recruiting

Study contacts

• Study coordinator: Menghua Tao, PhD
• Email: mtao1@hfhs.org
• Phone: 313-590-9408

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ultraportable Hepatoscope ultrasound for measuring liver fat in MASLD/MASH

  The Hepatoscope device will be tested to see if it can measure liver fat accurately in adults with MASLD/MASH compared with MRI-PDFF.

  Recruiting at 2 sites E-Scopics · Angers and 2 other locations · NCT06661655

• Non-invasive tool to predict fatty liver disease

  This study is testing a new, non-invasive tool to see if it can help identify fatty liver disease in healthy people and those already diagnosed with it.

  Recruiting Richmond Pharmacology Limited · London, London · NCT04873258

• Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD

  This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.

  Recruiting National University Health System, Singapore · Singapore, Singapore · NCT07861191

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Photon-counting CT and ultrasound for detecting liver fat and scarring

  This will test whether a new photon-counting CT plus ultrasound can find liver fat and scarring in adults with fatty liver or liver fibrosis, using MRI as the reference.

  Recruiting Duke University · Durham, North Carolina · NCT07495332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.